Cytogen (217330.KQ) Stock Price

Cytogen Price

CLOSED
3,425.00KRW+110.00 (+3.26 %)
Market closed

Revenue at Cytogen has contracted by 24.0% per year over the past 11 years to 26.05 B KRW. Cytogen's net margin stands at -47.4%, up from -3,125.1% several years earlier. The stock trades about 48% above its 52-week low.

Cytogen stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Cytogen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cytogen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cytogen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Cytogen Stock Price History
DateCytogen Price
8/5/20263,425.00 KRW
8/4/20263,315.00 KRW
8/3/20263,155.00 KRW
7/31/20263,000.00 KRW
7/30/20262,825.00 KRW
7/29/20262,845.00 KRW
7/28/20263,025.00 KRW
7/27/20263,120.00 KRW
7/24/20263,115.00 KRW
7/23/20263,135.00 KRW
7/22/20263,035.00 KRW
7/21/20262,980.00 KRW
7/20/20262,945.00 KRW
7/16/20263,050.00 KRW
7/15/20263,085.00 KRW
7/14/20262,920.00 KRW
7/13/20263,040.00 KRW
7/10/20263,115.00 KRW
7/9/20262,930.00 KRW
7/8/20262,965.00 KRW
7/7/20263,000.00 KRW
7/6/20263,055.00 KRW
7/3/20263,020.00 KRW
7/2/20263,000.00 KRW
7/1/20263,225.00 KRW
6/30/20263,170.00 KRW
6/29/20263,250.00 KRW
6/26/20262,945.00 KRW
6/25/20262,990.00 KRW
6/24/20263,215.00 KRW
6/23/20263,240.00 KRW
6/22/20263,535.00 KRW
6/19/20263,840.00 KRW
6/18/20264,005.00 KRW
6/17/20264,305.00 KRW
6/16/20264,150.00 KRW
6/15/20264,230.00 KRW
6/12/20264,195.00 KRW
6/11/20264,020.00 KRW
6/10/20264,010.00 KRW
6/9/20264,025.00 KRW
6/8/20263,960.00 KRW
6/5/20264,050.00 KRW
6/4/20264,340.00 KRW
6/2/20263,975.00 KRW
6/1/20264,355.00 KRW
5/29/20264,255.00 KRW
5/28/20264,510.00 KRW
5/27/20264,840.00 KRW
5/26/20265,080.00 KRW
5/22/20264,800.00 KRW
5/21/20264,600.00 KRW
5/20/20264,585.00 KRW
5/19/20264,670.00 KRW
5/18/20264,930.00 KRW
5/15/20265,230.00 KRW
5/14/20265,150.00 KRW
5/13/20265,140.00 KRW
5/12/20265,370.00 KRW
5/11/20265,400.00 KRW
5/8/20265,980.00 KRW
5/7/20266,210.00 KRW
5/6/20266,670.00 KRW
5/4/20266,160.00 KRW
4/30/20265,900.00 KRW
4/29/20265,730.00 KRW
4/28/20265,710.00 KRW
4/27/20265,580.00 KRW
4/24/20265,050.00 KRW
4/23/20265,240.00 KRW
4/22/20264,710.00 KRW
4/21/20264,930.00 KRW
4/20/20264,825.00 KRW
4/17/20264,300.00 KRW
4/16/20264,130.00 KRW
4/15/20264,130.00 KRW
4/14/20263,975.00 KRW
4/13/20263,955.00 KRW
4/10/20264,035.00 KRW
4/9/20263,945.00 KRW
4/8/20264,040.00 KRW
4/7/20263,835.00 KRW
4/6/20263,980.00 KRW
4/3/20263,955.00 KRW
4/2/20263,890.00 KRW
4/1/20264,650.00 KRW
3/31/20264,245.00 KRW
3/30/20264,540.00 KRW
3/27/20264,720.00 KRW
3/26/20264,750.00 KRW
3/25/20264,895.00 KRW
3/24/20265,200.00 KRW
3/23/20264,925.00 KRW
3/20/20265,360.00 KRW
3/19/20264,535.00 KRW
3/18/20264,670.00 KRW
3/17/20264,685.00 KRW
3/16/20264,650.00 KRW
3/13/20264,740.00 KRW
3/12/20264,630.00 KRW
3/11/20264,650.00 KRW
3/10/20264,525.00 KRW
3/9/20264,380.00 KRW
3/6/20264,640.00 KRW
3/5/20264,875.00 KRW
3/4/20264,435.00 KRW
3/3/20264,915.00 KRW
2/27/20265,480.00 KRW
2/26/20265,710.00 KRW
2/25/20266,160.00 KRW
2/24/20266,060.00 KRW
2/23/20266,210.00 KRW
2/20/20266,250.00 KRW
2/19/20266,330.00 KRW
2/13/20266,410.00 KRW
2/12/20266,620.00 KRW
2/11/20266,810.00 KRW
2/10/20266,940.00 KRW
2/9/20266,980.00 KRW
2/6/20266,800.00 KRW
2/5/20267,300.00 KRW
2/4/20267,400.00 KRW
2/3/20267,550.00 KRW
2/2/20267,540.00 KRW
1/30/20267,680.00 KRW
1/29/20267,980.00 KRW
1/28/20268,250.00 KRW
1/27/20267,800.00 KRW
1/26/20267,890.00 KRW
1/23/20268,030.00 KRW
1/22/20268,300.00 KRW
1/21/20268,680.00 KRW
1/20/20269,270.00 KRW
1/19/20269,420.00 KRW
1/16/20268,980.00 KRW
1/15/20267,820.00 KRW
1/14/20267,140.00 KRW
1/13/20267,600.00 KRW
1/12/20267,960.00 KRW
1/9/20268,200.00 KRW
1/8/20267,940.00 KRW
1/7/20268,250.00 KRW
1/6/20268,820.00 KRW
1/5/20269,100.00 KRW
1/2/20269,110.00 KRW
12/30/20258,990.00 KRW
12/29/20259,220.00 KRW
12/26/20258,910.00 KRW
12/24/20258,000.00 KRW
12/23/20256,680.00 KRW
12/22/20258,120.00 KRW
12/19/20256,250.00 KRW
12/18/20255,160.00 KRW
12/17/20255,140.00 KRW
12/16/20254,700.00 KRW
12/15/20254,000.00 KRW
12/12/20253,905.00 KRW
12/11/20253,900.00 KRW
12/10/20253,600.00 KRW
12/9/20253,805.00 KRW
12/8/20253,270.00 KRW
12/5/20253,410.00 KRW
12/4/20253,515.00 KRW
12/3/20253,490.00 KRW
12/2/20253,415.00 KRW
12/1/20253,400.00 KRW
11/28/20253,365.00 KRW
11/27/20253,330.00 KRW
11/26/20253,405.00 KRW
11/25/20253,410.00 KRW
11/24/20253,360.00 KRW
11/21/20253,120.00 KRW
11/20/20253,290.00 KRW
11/19/20253,265.00 KRW
11/18/20253,265.00 KRW
11/17/20253,395.00 KRW
11/14/20253,085.00 KRW
11/13/20253,175.00 KRW
11/12/20252,930.00 KRW
11/11/20252,780.00 KRW
11/10/20252,820.00 KRW
11/7/20252,865.00 KRW
11/6/20252,840.00 KRW
11/5/20252,975.00 KRW
11/4/20252,860.00 KRW
11/3/20252,805.00 KRW
10/31/20252,875.00 KRW
10/30/20252,785.00 KRW
10/29/20252,925.00 KRW
10/28/20253,070.00 KRW
10/27/20253,005.00 KRW
10/24/20253,100.00 KRW
10/23/20253,265.00 KRW
10/22/20253,000.00 KRW
10/21/20252,920.00 KRW
10/20/20252,980.00 KRW
10/17/20253,155.00 KRW
10/16/20253,090.00 KRW
10/15/20253,120.00 KRW
10/14/20253,215.00 KRW
10/13/20253,350.00 KRW
10/10/20253,605.00 KRW
10/2/20252,770.00 KRW
10/1/20252,565.00 KRW
9/30/20252,495.00 KRW
9/29/20252,365.00 KRW
9/26/20252,320.00 KRW
9/25/20252,380.00 KRW
9/24/20252,455.00 KRW
9/23/20252,430.00 KRW
9/22/20252,405.00 KRW
9/18/20252,535.00 KRW
9/17/20252,535.00 KRW
9/16/20252,535.00 KRW
9/15/20252,530.00 KRW
9/12/20252,645.00 KRW
9/11/20252,670.00 KRW
9/10/20252,670.00 KRW
9/9/20252,670.00 KRW
9/8/20252,770.00 KRW
9/5/20252,630.00 KRW
9/4/20252,675.00 KRW
9/3/20252,665.00 KRW
9/2/20252,660.00 KRW
9/1/20252,695.00 KRW
8/29/20252,730.00 KRW
8/28/20252,685.00 KRW
8/27/20252,675.00 KRW
8/26/20252,695.00 KRW
8/25/20252,695.00 KRW
8/22/20252,740.00 KRW
8/21/20252,740.00 KRW
8/20/20252,720.00 KRW
8/19/20252,775.00 KRW
8/18/20252,825.00 KRW
8/14/20252,690.00 KRW
8/13/20252,760.00 KRW
8/12/20252,685.00 KRW
8/11/20252,770.00 KRW
8/8/20252,750.00 KRW
Access this data via the Eulerpool API
Get Free API Key

Cytogen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
1.23 B KRW
-2.63 B KRW
-2.60 B KRW
Jan 1, 2019
798.92 M KRW
-4.49 B KRW
-4.14 B KRW
Jan 1, 2020
642.67 M KRW
-6.59 B KRW
-4.89 B KRW
Jan 1, 2021
347.85 M KRW
-10.90 B KRW
-10.87 B KRW
Jan 1, 2022
760.78 M KRW
-15.48 B KRW
-18.77 B KRW
Jan 1, 2023
3.18 B KRW
-14.33 B KRW
-15.77 B KRW
Jan 1, 2024
10.91 B KRW
-17.59 B KRW
-17.12 B KRW
Jan 1, 2025
26.05 B KRW
-7.48 B KRW
-12.34 B KRW

Cytogen Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 4:42 AM
 
REVENUEB KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITT KRW
EBIT MARGIN%
NET INCOMET KRW
NET INCOME GROWTH%
SHARESM
201420152016201720182019202020212022202320242025
530.150.490.850.211.230.800.640.350.763.1810.9126.05
–-99.9173.62-75.85497.56-34.86-19.55-45.95119.02318.95242.65138.81
6.2712.6830.8612.6825.47-23.31-20.0916.4325.6626.5725.9321.55
33.250.060.260.030.31-0.19-0.130.060.200.852.835.61
-2.91–––––-0.01-0.01-0.02-0.01-0.02-0.01
-549.25-640.08-307.07-1,110.73-214.61-562.41-1,025.86-3,141.50-2,037.37-449.97-161.24-28.71
-2.02––––––-0.01-0.02-0.02-0.02-0.01
–-99.81-43.5821.92-0.8059.2918.07122.3872.69-15.998.55-27.90
5.635.635.635.635.635.635.635.635.635.635.635.63
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Cytogen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cytogen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cytogen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Cytogen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cytogen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Cytogen stock margins

The Cytogen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cytogen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cytogen.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
25.47 %
-214.58 %
-212.09 %
Jan 1, 2019
-23.37 %
-561.78 %
-518.30 %
Jan 1, 2020
-20.17 %
-1,024.92 %
-760.70 %
Jan 1, 2021
16.47 %
-3,133.86 %
-3,125.13 %
Jan 1, 2022
25.66 %
-2,035.37 %
-2,467.37 %
Jan 1, 2023
26.57 %
-449.94 %
-495.22 %
Jan 1, 2024
25.93 %
-161.24 %
-156.88 %
Jan 1, 2025
21.55 %
-28.71 %
-47.37 %

Cytogen Stock Revenue, EBIT, Earnings per Share

The Cytogen earnings per share therefore indicates how much revenue Cytogen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
217.52 KRW
-466.76 KRW
-461.34 KRW
Jan 1, 2019
141.81 KRW
-796.64 KRW
-734.98 KRW
Jan 1, 2020
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2021
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2022
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2023
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2024
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2025
0.00 KRW
0.00 KRW
0.00 KRW

Cytogen business model & stock analysis

Cytogen Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Cytogen historical P/E ratio, EBIT multiple, and P/S ratio

Cytogen annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Cytogen shares outstanding

The number of shares of Cytogen was 5.63 M in 2025. This indicates how many shares Cytogen is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
5.63 M Stocks
Jan 1, 2019
5.63 M Stocks
Jan 1, 2020
5.63 M Stocks
Jan 1, 2021
5.63 M Stocks
Jan 1, 2022
5.63 M Stocks
Jan 1, 2023
5.63 M Stocks
Jan 1, 2024
5.63 M Stocks
Jan 1, 2025
5.63 M Stocks

Cytogen stock splits

In Cytogen's history, there have been no stock splits.
Price targets and forecasts for Cytogen are not yet available.

Cytogen shareholder structure

% Name
30.78567%
CanDx Holdings Limited
CanDx Holdings Limited
14.46291%
Jeon (Byeong Hui)
Jeon (Byeong Hui)
5.37121%
Signature Investment Fund
Signature Investment Fund
0.00000%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.

Cytogen Executives and Management Board

18 members · avg. age 53 · 0 % women

Management

BG

Mr. Byeong Cheon Goh (70)

President, Director

–
JA

Ji Hun Ahn (43)

Co-Chief Executive Officer, Director · since 2024

–
BJ

Mr. Byeong Hui Jeon (65)

Co-Chief Executive Officer, Director · since 2025

–
YB

Mr. Yin Seong Baek (37)

Chief Financial Officer, Director

–
ML

Mr. Min Taek Lee (60)

Chief Marketing Officer, Vice President, Director

–
HL

Mr. Hae Cheon Lee (55)

Managing Director

–

Board of Directors

JK

Mr. Jeong Won Kim (48)

Director

–
JK

Jong Seok Kim (36)

Other Non-Executive Director

–
SM

Seung Gi Min (61)

Other Non-Executive Director

–
HS

Han Sang Song (38)

Other Non-Executive Director

–
GY

Gi Hong Yoo (55)

Other Non-Executive Director

–
NB

Mr. Nam Ho Bahng (62)

Non-Executive Independent Director

–

Cytogen Supply Chain

Cytogen Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
Eutilex
Customer·Biotechnology·KR
-0.08
0.42
-0.85
-0.22
-0.34
-0.35
2
Daiichi Sankyo
Customer·Pharmaceuticals·JP
-0.37
-0.30
0.74
0.46
0.39
-0.24

Frequently asked questions about Cytogen

Converted at the current exchange rate, the Cytogen share trades at 2.08 EUR (3,425.00 KRW).

No history available for Cytogen.

The revenue cannot currently be calculated for Cytogen.

The profit cannot currently be calculated for Cytogen.

The P/E ratio cannot be calculated for Cytogen at the moment.

The P/S cannot be calculated for Cytogen currently.

The Eulerpool Quality Score for Cytogen is 4/10.

The ISIN of Cytogen is KR7217330000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cytogen is 217330.KQ. The ticker symbol is used to trade Cytogen shares on the stock exchange.

Cytogen paid dividends every year for the past 0 years.

Cytogen is assigned to the 'Health' sector.

The dividends of Cytogen are distributed in KRW.

All fundamentals and in-depth analysis of Cytogen

Our stock analysis for Cytogen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytogen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Cytogen Stock
Cytogen Revenue→
Cytogen Stock
Cytogen Net Income→
Cytogen Stock
Cytogen P/E→
Cytogen Stock
Cytogen P/S→
Cytogen Stock
Cytogen EBIT→
Cytogen Stock
Cytogen Dividend→
Cytogen Stock
Cytogen Directors Dealings→
Cytogen Stock
Cytogen Stocks→
Cytogen Stock
Cytogen Market capitalization→
Cytogen Stock
Cytogen Debt→
Cytogen Stock
Cytogen Liabilities→
Cytogen Stock
Cytogen Equity→
Cytogen Stock
Cytogen AAQS→
Cytogen Stock
Cytogen Employees→
Cytogen Stock
Cytogen ROE→
Cytogen Stock
Cytogen ROA→
Cytogen Stock
Cytogen ROCE→
Cytogen Stock
Cytogen News→
Cytogen Stock
Cytogen Analyst Price Targets→

Health Stocks

CytokineticsCytodynCytoMed TherapeuticsCytek BiosciencesCytomX TherapeuticsCypherpunk TechnologiesCytosorbentsCynata TherapeuticsCyttaCyfuse Biomedical KKD.Western Therapeutics InstituteCyclopharmAll Stocks A–Z →